Back to Search
Start Over
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
- Source :
-
International journal of clinical and experimental pathology [Int J Clin Exp Pathol] 2012; Vol. 5 (4), pp. 278-89. Date of Electronic Publication: 2012 Apr 26. - Publication Year :
- 2012
-
Abstract
- Human aldo-keto reductase family 1 member C3 (AKR1C3) was initially identified as a critical enzyme in reducing 5α-dihydrotestosterone (5α-DHT) to 5α-androstane-3α,17β-diol (3α-diol) and oxidizing 3α-diol to androsterone. Based on these enzymatic activities, AKR1C3 was originally named type 2 3α-hydroxysteroid dehydrogenase (HSD)/type 5 17β-HSD. Additionally, AKR1C3 was demonstrated to be capable of metabolizing other steroids including estrogen and progesterone. Subsequently, AKR1C3 was shown to possess 11-ketoprostaglandin reductase activity in metabolizing prostaglandins and dihydrodiol dehydrogenase x (DDx) activity in metabolizing xenobiotics. Tissue distribution of AKR1C3 has been detected in both sex hormone-dependent organs such as the testis, breast, endometrium, and prostate as well as sex hormone-independent organs including the kidney and urothelium. Although prominent expression of AKR1C isozymes has been reported in human non-small cell lung carcinoma (NSCLC), the expression of AKR1C3 in small cell carcinoma of the lung has not been described. Also, the expression of AKR1C3 in normal lung has not been described. In this study, we demonstrated strong AKR1C3 immunoreactivity in bronchial epithelium but not in bronchial glands or alveolar pneumocytes. Strong AKR1C3 immunoreactivity was also demonstrated in columnar epithelium but only weak immunoreactivity in squamous epithelium of the gastrointestinal junction. Although AKR1C3 immunoreactivity was absent in small cell carcinoma of the lung, positive AKR1C3 immunoreactivity was extensively present in both adenocarcinoma and squamous cell carcinoma arising from the lung and the gastroesophageal junction. AKR1C3 may serve as an adjunct marker for differentiating small cell carcinoma from NSCLC. However, roles of AKR1C3 in adenocarcinoma, squamous cell carcinoma, and small cell carcinoma pathogenesis require further studies.
- Subjects :
- Adenocarcinoma pathology
Adenocarcinoma of Lung
Adult
Aged
Aged, 80 and over
Aldo-Keto Reductase Family 1 Member C3
Carcinoma, Squamous Cell pathology
Diagnosis, Differential
Esophageal Neoplasms pathology
Esophagogastric Junction pathology
Female
Humans
Immunohistochemistry
Lung Neoplasms pathology
Male
Middle Aged
Oklahoma
Predictive Value of Tests
Small Cell Lung Carcinoma pathology
Stomach Neoplasms pathology
3-Hydroxysteroid Dehydrogenases analysis
Adenocarcinoma enzymology
Biomarkers, Tumor analysis
Carcinoma, Squamous Cell enzymology
Esophageal Neoplasms enzymology
Esophagogastric Junction enzymology
Hydroxyprostaglandin Dehydrogenases analysis
Lung Neoplasms enzymology
Small Cell Lung Carcinoma enzymology
Stomach Neoplasms enzymology
Subjects
Details
- Language :
- English
- ISSN :
- 1936-2625
- Volume :
- 5
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- International journal of clinical and experimental pathology
- Publication Type :
- Academic Journal
- Accession number :
- 22670171